Back My treatment worked and there is little or no cancer left No cancer after treatment for recurrence

Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.

This search will output a list of trials for which you may be eligible based on the criteria you enter.

I want to enter information about my cancer and treatments

I want to enter information about my genetic testing (e.g, BRCA) and/or tumor testing results

I want to filter the trials based on location, phase of development, tumor genomic alteration, or drug name, category or target

Matching Trials

For more detailed information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.
For a key to the icons and text used in the Results column, please click here.
To learn more about our trial annotation process, results assignments, and the criteria used to highlight drugs with promising results, please click here.

NCT05329545

III

High grade serous NaPi2b+ ovarian cancer with platinum-sensitive recurrence and CR, PR or SD in most recent platinum-based therapy; no avastin with most recent platinum-based therapy (maintenance)

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants With Recurrent, Platinum-Sensitive, Ovarian Cancer (UP-NEXT)

CO, FL, GA, ME, MO, MT, NV, NM, NC, OH, OK, OR, RI, TN, TX

View Drugs

View Results

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Placebo
Upifitamab rilsodotin	XMT-1536, UpRi	ADC: anti-NaPi2b + microtubule destabilizer (auristatin F-HPA)	Clinical Trials

NCT05445778

III

High grade serous FRalpha high+ ovarian cancer with platinum-sensitive recurrence and CR, PR or SD in most recent platinum-based therapy, must have avastin with most recent platinum-based therapy (maintenance)

Randomized, Multicenter, Open-label, Phase 3 Study of Mirvetuximab Soravtansine in Combination With Bevacizumab Versus Bevacizumab Alone as Maintenance Therapy for Patients With FRα-positive Recurrent Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers Who Have Not Progressed After Second Line Platinum-based Chemotherapy Plus Bevacizumab

View Drugs

View Results

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Bevacizumab	Avastin, anti-VEGF monoclonal antibody, immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain	VEGF antagonist	Approved in Ovarian Cancer
Mirvetuximab soravtansine	M9346A-sulfo-SPDB-DM4, IMGN853, Anti-FOLR1-mab Maytansinoid Conjugate	ADC: anti-FOLR1 + microtubule destabilizer (DM4)	Approved in Ovarian Cancer

NCT04804007

Germ cell tumors after treatment with high-dose chemotherapy (HDCT) and peripheral-blood stem-cell transplant (PBSCT) (maintenance)

Randomized Phase 2 Trial of Maintenance Oral Etoposide or Observation Following High-dose Chemotherapy for Relapsed Metastatic Germ-Cell Tumor

View Drugs

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Etoposide	VePesid, Toposar, Lastet, epipodophyllotoxin	Topoisomerase II inhibitor

If you have any questions or would like help with your search, please call us at: 858-657-0282 or email us at patientsupport@clearityfoundation.org.

Matching Trials

Contact Us